Power Law company profile

AnaptysBio

Biotech & Life Sciences · San Diego, United States · Founded 2005 · IPO 2017 Unicorn

Antibody therapeutics based on somatic hypermutation

Valuation

$1.52B

Market cap · Apr/2026

Revenue

$235M

Latest reported FY

EBITDA

$69M

Latest reported FY

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026 $10B+ revenueThoroughbred · Power Law outcome

Investors

11 investors on AnaptysBio's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 1 investor entered at this stage

Avalon Ventures

Series B+ 10 investors entered at this stage

Cormorant Asset Management

BVF Partners

Frazier Healthcare Partners

BioMed Ventures

Numenor Ventures

HBM Healthcare Investments

Novo Holdings

Novo Seeds

Alloy Ventures

WS Investments

Global footprint

Where AnaptysBio has talent and traffic

Workforce by country

🇺🇸 United States · San Diego HQ

Book a demo for the full country breakdown

Web traffic by country

11K monthly visits
across markets

🇺🇸 United States85.5%

🇮🇳 India10%

🇯🇵 Japan9.1%

Top 3 markets shown

Market sentiment

What the market is saying about AnaptysBio

An AI-synthesized read of the highest-engagement posts about AnaptysBio on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See AnaptysBio on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles